Research comparison
A side-by-side comparison of BPC-157 and TB-500 as they are characterised in the peer-reviewed research literature. Connective-tissue and wound-healing research. Both compounds are supplied for in-vitro laboratory research only.
| BPC-157 | TB-500 | |
|---|---|---|
| Research area | Regenerative Research | Regenerative Research |
| Sizes stocked | 2mg, 5mg, 10mg | 2mg, 5mg, 10mg |
| Reference | Full BPC-157 page → | Full TB-500 page → |
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of human gastric juice protein. Characterised in preclinical literature for its stability profile and effects on connective-tissue and gastrointestinal cell-signalling models. Supplied as lyophilised powder for in-vitro research use only.
TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid peptide characterised in the literature for its role in actin sequestration and cellular migration in preclinical models. Supplied as lyophilised powder for in-vitro research use only.
Both compounds are characterised in the research literature within connective-tissue and wound-healing research. Researchers typically consult the primary peer-reviewed publications for each compound before selecting one for a specific experimental protocol. The two are frequently studied in parallel and occasionally cited together in comparative pharmacology reviews.
Both BPC-157 and TB-500 are supplied as lyophilised powder and reconstituted with bacteriostatic water using standard laboratory technique. For full reconstitution methodology see our Research Handling Guide, or compute resulting mg/ml concentrations with the Reconstitution Volume Calculator.
Every batch of both compounds is independently HPLC-verified by Janoshik Analytical at 99%+ purity. The lab report is supplied with every order and carries a unique verification key.